← All trials
NCT07176208
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2025
- Primary completion
- Feb 27, 2026
- Completion date
- Feb 27, 2026
- First posted
- Sep 16, 2025
- Last posted
- Sep 16, 2025
- Enrollment
- 48
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Food and Drug AdministrationLead sponsor
- Spaulding Clinical Research Inc.Official
- Spaulding Clinical Research Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.